Search PubMed⌕ Search

Biomedical subjects

J Rostkowska

Publications and source records attributed to J Rostkowska.

At least 19 recordsLinked to original sources
PubMed1991

[Evaluation of the usefulness of measuring the serum and urine levels of light chain immunoglobulins in multiple myeloma and Waldenström's macroglobulinemia].

Quantitative determinations were carried out of light immunoglobulin chains by the method of ring precipitation in the serum and urine of 117 patients with plasmocytic myeloma and 16 with Waldenström's macroglobulinemia. The method was found useful for the identification of the light chain of the monoclonal proteins of IgG, and IgD classes. In the case of the lambda-type light chain disease the method is helpful in the identification of the M-component of the serum. Quantitative determination of light chains of immunoglobulins by ring precipitation is not essentially superior to other immunological and electrophoretic methods of protein analysis in monitoring treatment of cases of this myeloma.

Humans↗
PubMed1991

[Therapeutic plasmapheresis in patients with multiple myeloma].

The effectiveness of therapeutic plasmaphereses with antineoplastic chemotherapy was evaluated in 25 cases of plasmocytic myeloma in stage III of progression of the proliferative process. The indication to plasmapheresis was hypergelification of serum with clinical symptoms of central nervous system disturbances, renal failure in various stages of progression, intensification of coronary symptoms, bleeding tendency. Good effects with reduced level of total protein and monoclonal protein in serum by 30-80% with regression of clinical symptoms caused by serum hypergelification were obtained in 11 cases. In the remaining patients clinical improvement of varying degree was noted when the level of total and monoclonal protein in the serum fell by 10-29%.

Adult↗
PubMed1991

[Chemotherapy and immunomodulating treatment of patients with multiple myeloma].

Prospective studies were carried out on the effectiveness of various treatment methods in 208 patients with plasmocytic myeloma. In 102 patients induction therapy was based exclusively on melphalan, in 106 cases polychemotherapy was used including vincristine, melphalan, carmustine, cyclophosphamide and prednisone. The differences in the per cent of patients with good response to treatment and in the survival time after treatment beginning were statistically not significant between these groups which suggests that polychemotherapy begun from the diagnosis of the disease is justified in patients with large mass of the neoplasm and poor prognostic factors. In 45 patients chemotherapy was supported by administration of immunomodulatory agents, including calf thymus extract in 25 cases, levamisole in 18 and interferon in 2. It was observed that maintenance of remission with chemotherapy and with immunomodulatory agents calf thymus extract or levamisole prolonged the survival of the patients. In cases of leucopenia the use of calf thymus extract facilitated chemotherapy by stimulation of myelopoiesis.

Adult↗
PubMed1991

[Clinical and laboratory analysis of the cases of multiple myeloma with over 5-year survival time from the beginning of the antineoplastic treatment].

Out of 436 studied patients with plasmocytic myeloma 67 (15.0%) survived over 5 years from the beginning of antineoplastic treatment, and 18 survived over 10 years from the first symptom of the proliferative process. The patients with long survival were younger at the time of diagnosis than the whole studied group and had normal creatinine and calcium levels in the serum. Nearly half these patients had I or II stage of clinical progression and IgG monoclonal protein. Treatment with melphalan only was given to 17 patients, 33 were treated with melphalan, followed by vincristine, cyclophosphamide, BCNU, prednisone and doxorubicin. Polychemotherapy was given from the time of the diagnosis to 13 patients, and 4 received radiotherapy or 60Co irradiation besides chemotherapy. In 81% of the analysed cases a good response was obtained. Thirteen patients are alive. In 5 cases myeloid leukaemia, in 1 case bronchogenic carcinoma and in 1 case liver carcinoma were the causes of death.

Adult↗
PubMed1979

[Plasmacytoma].

Explore the source record for details and available documents.

Aged↗
PubMed1979

Determination of subclasses of myeloma proteins M-IgG by enzymatic hydrolysis.

Several methods of determine M-IgG subclasses after hydrolysis with papain and pepsin were compared, and the results were checked by the passive hemagglutination test with erythrocytes using specific antisera. For practical purposes, the papain method was preferred to the pepsin method for recognition of IgG-3 subclass. A shortened method of digestion with papain which distinguishes between the papain-sensitive subclasses, i.e. IgG-1 and IgG-3, is proposed. Apart from its diagnostic value in distinguishing between myeloma (monoclonal) protein subclasses, this work can serve as a basis for preparing protein antigens and production of specific antisera.

Antibodies, Neoplasm↗
PubMed1979

[Analysis of the results of treatment of multiple myeloma].

Therapeutic results were analysed in 62 cases of multiple myeloma treated by two-stage method: I. with cyclically non-specific agents (melphalan) in each case. When this treatment was a failure the second step was given: II. cyclically specific and non-specific agents by the M-2 schedule. Good therapeutic response was obtained in 70% of cases. The mean survival time in the whole group was 35 months, and in the subgroup with good prognosis it was 44 months. Most (74%) patients with IgG M-protein responded well to treatment with cyclically non-specific agents, while only 50% of those with IgA M-protein had a good response to them.

Adult↗
PubMed1977

Serum levels of IgE in malignant lymphogranulomatosis.

Serum levels of IgE in malignant lymphogranulomatosis (Hodgkin's disease) were lowered in patients who had been intensively treated, without eosinophilic granulocytes, and in less advanced forms of the disease. High levels were observed in untreated patients with eosinophilic granulocytes in their peripheral blood, and in clinically advanced cases.

Granulocytes↗
PubMed1976

[M-component of serum formed by lambda-type Bence-Jones protein].

M-component in the serum composed of free light chains occurs rarely as evidenced by literature. In the investigations of the authors it was demonstrated that three M components obtained from patients with plasmocytoma were composed of free light chains type lambda. High concentration of low-molecular protein in serum was due, probably, to coexistent impairment of renal filtration. It is worth stressing that M component was a lambda-type chain which may explain the pathogenesis of renal failure caused by amyloidosis.

Amyloidosis↗